CORTIMENT Therapy for Ulcerative Colitis Receives Marketing Approval in Europe

CORTIMENT Therapy for Ulcerative Colitis Receives Marketing Approval in Europe
Ferring Pharmaceuticals’ CORTIMENT (budesonide), a treatment for ulcerative colitis indicated for the induction of remission in patients who have an active, mild to moderate form of the disease, recently received marketing approval by the European Union through the EU’s Mutual Recognition Procedure. The drug was already available in the Netherlands since 2013, and the company now plans on launching it in

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *